Corrigendum: Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors Via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance
Xixi Lin,Yongliang Jia,Xinwei Dong,Jian Shen,Yachao Jin,Yanyou Li,Fang Wang,Eitan Anenberg,Jiancang Zhou,Jianping Zhu,Xiaoping Chen,Qiangmin Xie,Yicheng Xie
DOI: https://doi.org/10.3389/fphar.2022.890886
IF: 5.6
2022-01-01
Frontiers in Pharmacology
Abstract:Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance. By Lin, X., Jia, Y., Dong, X., Shen, J., Jin, Y., Li, Y., Wang, F., Anenberg, E., Zhou, J., Zhu, J., Chen, X., Xie, Q., Xie, Y. (2019) Frontiers in Pharmacology. 10:982. doi: 10.3389/fphar.2019.00982.In the original article, there was a mistake in Figure 3H as published. An incorrect image for the p53 measurement in A549 was shown. The corrected Figure 3H appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.